Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

ADHD task force concerned over long waiting time for patients

The task force has called for timely recognition and early support for suspected ADHD cases, particularly in schools, to prevent future adverse impacts

ADHD is a neurodevelopmental disorder with symptoms including impulsiveness, disorganisation and difficulty focusing.

ADHD is a neurodevelopmental disorder with symptoms including impulsiveness, disorganisation and difficulty focusing.

iStock

AN independent taskforce on attention deficit hyperactivity disorder (ADHD) care has expressed concern over the long NHS waiting time and the growth of private providers that are not regulated, resulting in two-tier access to services.

The task force, chaired by professor Anita Thapar, was launched last year by NHS England, along with the government.


ADHD is a neurodevelopmental disorder with symptoms including impulsiveness, disorganisation and difficulty focusing.

The task force has called for timely recognition and early support for suspected ADHD cases, particularly in schools, to prevent future adverse impacts.

The report, citing recent data, claims that there is a high level of under-recognition and under-treatment of those diagnosed with ADHD, and minority groups face "significant inequalities" in access to care.

The report claimed the estimated economic costs of not treating ADHD are around £17 billion to the UK economy.

This could be in the form of lower tax contributions, receipt of more state benefits, long-term unemployment, and higher costs for health and social care.

English population data show that among young people who are not in education, employment, or training (NEET), 20–34 per cent are likely to have ADHD.

Many of these costs are avoidable, as with appropriate, early support, the task force observed.

The report pointed out that the inability to access NHS services has led to a significant growth in the use of unregulated private providers.

This has resulted in two-tier access to services, diagnosis, and treatment; one for those who can pay and another for those who cannot.

This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment, and health, the report noted.

It called upon the modernisation of NHS services, "as well as join-up with other sectors, as not all support needs to be provided by health care."

Professor Anita Thapar said the task force recommendations will require "action across government and cross-sector organisations to make the necessary changes to improve the lives of people with ADHD."

NHS England’s Medical Director for Mental Health and Neurodiversity Dr Adrian James said, “It is clear that much more needs to be done to improve ADHD assessment and care in England and ensure people can get a timely diagnosis, and we welcome the findings from the interim report, and look forward to its final conclusions later this year”.

He claimed that NHS England has rolled out some measures to improve ADHD care.

These include a data improvement plan and the first-ever publicly available reporting on ADHD referrals and waiting times, which began last month.

Over time, this will help local teams better understand how they are performing and where they need to improve care and patient experience, he said.

He said by March 2026, 6 in 10 pupils will have access to a mental health support team in school.

Teachers are being trained to better identify and support neurodiverse pupils and engage with their families, under the Partnership for Inclusion of Neurodiversity in Schools Programme, James added.

More For You

Experts say chronic fatigue is rooted in the body not the mind

Chronic fatigue impacts around 50,000 people in Scotland.

Pic credit: iStock

Experts say chronic fatigue is rooted in the body not the mind

Myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS) is a result of differences in the blood of patients compared to their healthy counterparts, say experts.

The differences in blood was associated with chronic inflammation, insulin resistance and liver disease.

Keep ReadingShow less
US approves Gilead's twice-yearly injection to prevent HIV

A trial involving more than 2,000 women in sub-Saharan Africa resulted in a 100 percent reduction in infections.

US approves Gilead's twice-yearly injection to prevent HIV

The US Food and Drug Administration has approved Gilead Sciences' twice-yearly injection to prevent HIV - a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections.

Keep ReadingShow less
Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less